Research

A New Paradigm for Type 1 Diabetes Origin

A New Paradigm for Type 1 Diabetes Origin

We spoke with Ajit Shah, PhD and Peter Thompson, PhD about their research which has just been published in Cell Metabolism. This UC San Francisco study of human and mouse pancreatic tissue suggests a new origin story for type 1…
Path to Better Clinical Trials for T1D Delay/Prevention

Path to Better Clinical Trials for T1D Delay/Prevention

The Critical Path Institute (C-Path) is a catalyst in the development of new approaches including biomarkers and modeling and analysis tools to support clinical trial design and clinical outcome assessments. C-Path forms and leads consortiums that include drug developers, academics,…
BCG Vaccine Shows Promising Signals of T1D Efficacy

BCG Vaccine Shows Promising Signals of T1D Efficacy

We spoke with Denise Faustman, MD, Ph.D., Director of Immunobiology Massachusetts General Hospital, and Associate Professor of Medicine Harvard Medical School.  The following is a summary of the research that she and her team are working on. Early Islet Trials I…
T1D Delay/Prevention in at-risk Children

T1D Delay/Prevention in at-risk Children

We spoke with Pieter Rottiers, Ph.D., CEO of ActoBio Therapeutics. Genetic testing, combined with existing NIH TrialNet procedures, has shown very positive results in predicting T1D (see article). Intervention at the earliest possible time is expected to improve outcomes for…
Sernova Cell Pouch Hopes to Improve Islet Transplant Success

Sernova Cell Pouch Hopes to Improve Islet Transplant Success

Sernova is a regenerative medicine company located in London, Ontario. The corporation is led by President and CEO Dr. Philip M. Toleikis (bio) who has a strong background in implantable medical devices from twenty years in leadership roles including Angiotech…
JDRF bets that Pandion Can Help

JDRF bets that Pandion Can Help

We spoke with Anthony Coyle, Ph.D., Co-founder and CEO of Pandion Therapeutics which is located in Cambridge Massachusetts.  This interview was stimulated by the JDRF announcement of their investment in Pandion. Paradigm Change Pandion is trying to shift the paradigm for the treatment…
Vaccine for T1D in Clinical Trials Soon

Vaccine for T1D in Clinical Trials Soon

INTRODUCTION Virus infections have long been considered as a possible cause of type 1 diabetes. One virus group, enteroviruses (EVs), has been studied extensively, and clinical development of a vaccine against T1D-associated EV types has started. “Epidemiological and experimental studies…
Regrowth of Human Beta Cells for T1D and T2D

Regrowth of Human Beta Cells for T1D and T2D

Effective Therapeutic Rate A combination of two drugs enhances the production of beta cells such that they proliferate at the highest rate ever observed in humans – a rate of 5 to 8 percent per day. “Beta cell regeneration is…
Understanding Pancreas Cell Development

Understanding Pancreas Cell Development

Prof. Dr. Henrik Semb who led the study explains his recent paper in Nature. Dr. Semb and his team have discovered the signals that determine the fate of immature cells in the pancreas. The research shows that they are very…
Seraxis Islet Technology Aims for Practical T1D Cure

Seraxis Islet Technology Aims for Practical T1D Cure

Islet transplants offer the hope of a permanent cure for Type 1 Diabetes.  After nearly six years in stealth mode, Seraxis has emerged as a front-runner in the race to clinical islet deployment.  Privately funded, and without any NIH or…
Leveraging T2D Drugs to improve T1D Therapy

Leveraging T2D Drugs to improve T1D Therapy

Paresh Dandona, MD, Ph.D. (bio) has been passionate about blood sugar control since he became a Fellow in London in 1975.  He joined the faculty of the University of Buffalo School of Medicine in 1995 and has a remarkable track…
Pramlintide Reimagined and Results are Promising

Pramlintide Reimagined and Results are Promising

Over a decade ago, the US approval and launch of pramlintide (Symlin® AstraZeneca) brought a lot of excitement because of its therapeutic ability, when used in combination with mealtime insulin, to flatten post-meal blood glucose levels, reduce glucose excursions, and…
Could bacteria be causing diabetes?

Could bacteria be causing diabetes?

The relationship between gut bacteria, genetics, and T1D risk is a complicated picture, but multiple studies indicate that gut bacteria is an essential factor. TEDDY The Environmental Determinants of Diabetes in the Young (TEDDY) is on ongoing, multi-study effort that…
Metformin May Improve Vascular Health in T1D Adolescents

Metformin May Improve Vascular Health in T1D Adolescents

Cardio vascular disease is the leading cause of mortality in people with T1D.   This relates strongly to insulin resistance and both lean and obese T1D adolescents have marked insulin resistance. Metformin is known to improve surrogate markers of insulin resistance…
Update on Inhaled Insulin

Update on Inhaled Insulin

Rapid-acting insulins such as Novolog and Humalog often show peak insulin levels up to 3 hours after injection.  In this period, glucose levels may fluctuate considerably.  Inhaled insulin starts working more quickly and peaks in less than one hour. Diabetes…
Race to introduce a T1D drug that inhibits glucose absorption

Race to introduce a T1D drug that inhibits glucose absorption

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, also called gliflozin drugs, are a new class of diabetic medications. They work by reducing the re-absorption of glucose into the blood via the kidneys with the excess glucose urinated. The FDA has already approved…
Insulin could be a Possible New Therapy for Colitis

Insulin could be a Possible New Therapy for Colitis

Insulin is widely used to treat diabetes, and it may be beneficial in treating other conditions.
Maternal Gluten Intake Linked to T1D in Children

Maternal Gluten Intake Linked to T1D in Children

A study in Denmark covering more than 67,000 pregnancies mothers has revealed that mothers that consumed 20 g/day of gluten had double the risk of T1D development in their offspring!
New predictors are a lifeline for families living with Type 1 Diabetes

New predictors are a lifeline for families living with Type 1 Diabetes

Combining genetic testing with existing NIH TrialNet procedures has shown very positive initial results in predicting T1D.*
New Type 1 Therapy Promises Long-term Diabetes Reversal in Humans and Dogs

New Type 1 Therapy Promises Long-term Diabetes Reversal in Humans and Dogs

Preclinical animal study shows initial results on the first minimally invasive therapy to successfully reverse Type 1 diabetes within 24 hours and maintain insulin independence for at least 90 days.
Back to top button